ASSOCIAÇÃO ENTRE INTERLEUCINAS 1β, 6 E 8 E A CONDIÇÃO PÓS-COVID: UMA REVISÃO SISTEMÁTICA COM METANÁLISE E ANÁLISE EXPLORATÓRIA DE FATORES DE RISCO
DOI:
https://doi.org/10.66104/ybqxd808Palavras-chave:
Biomarcadores , Condição Pós-COVID , COVID longa, Marcadores inflamatórios, Saúde PúblicaResumo
A condição pós-COVID (CPC) caracteriza-se pela persistência de sintomas após a infecção aguda por SARS-CoV-2, sendo associada a mecanismos inflamatórios sustentados. Esta revisão sistemática com metanálise avaliou os níveis de IL-1β, IL-6 e IL-8 em indivíduos com CPC, comparando-os a controles saudáveis e indivíduos recuperados sem sintomas persistentes. O protocolo foi registrado no PROSPERO (CRD42024610712) e conduzido conforme as diretrizes PRISMA 2020. Foram incluídos estudos observacionais que avaliaram concentrações séricas ou plasmáticas dessas citocinas. A qualidade metodológica foi analisada por instrumentos validados, e a diferença média padronizada (SMD) com IC95% foi estimada por modelos de efeitos fixos ou aleatórios. Vinte e cinco estudos, totalizando 3.927 participantes, foram incluídos. Indivíduos com CPC apresentaram níveis significativamente mais elevados de IL-1β, IL-6 e IL-8 em comparação a controles saudáveis. Em comparação a indivíduos recuperados, apenas a IL-1β permaneceu significativamente elevada. As análises apresentaram heterogeneidade de moderada a elevada entre os desfechos. Análises de subgrupo sugeriram influência da idade e da gravidade da infecção aguda. Os achados sustentam a hipótese de inflamação persistente na CPC, destacando a IL-1β como potencial biomarcador associado à persistência sintomática.
Downloads
Referências
ACOSTA-AMPUDIA, Y. et al. Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome. The Journal of Infectious Diseases, [S. l.], v. 225, n. 12, p. 2155–2162, 15 jun. 2022. Disponível em: https://doi.org/10.1093/infdis/jiac017. Acesso em: 11 abr. 2025.
AID, M. et al. Long COVID involves activation of proinflammatory and immune exhaustion pathways. Nature Immunology, [S. l.], v. 27, n. 1, p. 61–71, jan. 2026. Disponível em: https://www.nature.com/articles/s41590-025-02353-x. Acesso em: 23 fev. 2026.
AKBAR, A. N.; GILROY, D. W. Aging immunity may exacerbate COVID-19. Science, [S. l.], New York, N.Y., v. 369, n. 6501, p. 256–257, 17 jul. 2020.
AL-HAKEIM, H. K. et al. Chronic Fatigue, Depression and Anxiety Symptoms in Long COVID Are Strongly Predicted by Neuroimmune and Neuro-Oxidative Pathways Which Are Caused by the Inflammation during Acute Infection. Journal of Clinical Medicine, [S. l.], v. 12, n. 2, p. 511, 8 jan. 2023. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC9865328/. Acesso em: 10 jan. 2026.
ALONSO-DOMÍNGUEZ, J. et al. High Levels of IL-1β, TNF-α and MIP-1α One Month after the Onset of the Acute SARS-CoV-2 Infection, Predictors of Post COVID-19 in Hospitalized Patients. Microorganisms, [S. l.], v. 11, n. 10, p. 2396, 26 set. 2023. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10609568/. Acesso em: 10 jan. 2026.
ANANG, V. et al. SARS-CoV-2 innate immune recognition and implications for respiratory health. Cytokine & Growth Factor Reviews, [S. l.], v. 86, p. 167–180, dez. 2025.
BALDUZZI, S.; RÜCKER, G.; SCHWARZER, G. How to perform a meta-analysis with R: a practical tutorial. BMJ Mental Health, [S. l.], v. 22, n. 4, 23 out. 2019. Disponível em: https://mentalhealth.bmj.com/content/22/4/153. Acesso em: 9 maio 2025.
BERGANTINI, L. et al. Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19. Immunobiology, [S. l.], v. 229, n. 4, p. 152813, 1 jul. 2024. Disponível em: https://www.sciencedirect.com/science/article/pii/S0171298524000317. Acesso em: 10 jan. 2026.
BRASIL. Coronavírus Brasil - Ministério da Saúde. 2025. Disponível em: https://covid.saude.gov.br/. Acesso em: 11 set. 2024.
CAWLEY, A. Biomarker analysis. Drug Testing and Analysis, [S. l.], v. 14, n. 5, p. 791–793, 2022. Disponível em: https://onlinelibrary.wiley.com/doi/abs/10.1002/dta.3268. Acesso em: 1 ago. 2024.
CERVIA, C. et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nature Communications, [S. l.], v. 13, n. 1, p. 446, 25 jan. 2022. Disponível em: https://www.nature.com/articles/s41467-021-27797-1. Acesso em: 10 jan. 2026.
CORREIA, A. O. et al. Neurological manifestations of COVID-19 and other coronaviruses: A systematic review. Neurology, Psychiatry, and Brain Research, [S. l.], v. 37, p. 27–32, set. 2020.
DANI, M. et al. Autonomic dysfunction in “long COVID”: rationale, physiology and management strategies. Clinical Medicine, [S. l.], London, England, v. 21, n. 1, p. e63–e67, jan. 2021.
DAVIS, H. E. et al. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, [S. l.], v. 21, n. 3, p. 133–146, mar. 2023. Disponível em: https://www.nature.com/articles/s41579-022-00846-2. Acesso em: 23 fev. 2026.
DE GRANDA-ORIVE, J. I.; SOLANO-REINA, S.; JIMÉNEZ-RUIZ, C. A. Are Smoking and Vaping Risk Factors of Developing Long and Persistent Post-COVID-19? Open Respiratory Archives, [S. l.], v. 4, n. 4, p. 100195, 1 out. 2022. Disponível em: https://www.sciencedirect.com/science/article/pii/S2659663622000418. Acesso em: 2 jun. 2025.
DEEKS, J. et al. Chapter 10: Chapter 10: Analysing data and undertaking meta-analyses. nov. 2024. Cochrane Handbook for Systematic Reviews of Interventions. Disponível em: https://training.cochrane.org/handbook/current/chapter-10. Acesso em: 8 maio 2025. (version 6.5.).
DUINDAM, H. B. et al. Systemic inflammation relates to neuroaxonal damage associated with long-term cognitive dysfunction in COVID-19 patients. Brain, Behavior, and Immunity, [S. l.], v. 117, p. 510–520, mar. 2024.
ELY, E. W.; BROWN, L. M.; FINEBERG, H. V. Long Covid Defined. New England Journal of Medicine, [S. l.], v. 391, n. 18, p. 1746–1753, 6 nov. 2024. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMsb2408466. Acesso em: 27 fev. 2025.
FERREIRA, A. C. et al. SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes. Cell Death Discovery, [S. l.], v. 7, n. 1, p. 43, 1 mar. 2021.
FERREIRA, A. M. S. et al. Symptoms and Risk Factors for Long COVID: A Cross-Sectional Study in Primary Care. Journal of Medical Virology, [S. l.], v. 97, n. 9, p. e70579, 2025. Disponível em: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.70579. Acesso em: 19 fev. 2026.
FISCHER, C. et al. SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition. NPJ Vaccines, [S. l.], v. 9, p. 23, 5 fev. 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10844289/. Acesso em: 10 jan. 2026.
FRANCESCHI, C. et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nature Reviews. Endocrinology, [S. l.], v. 14, n. 10, p. 576–590, out. 2018.
GANESH, R. et al. The Female-Predominant Persistent Immune Dysregulation of the Post-COVID Syndrome. Mayo Clinic Proceedings, [S. l.], v. 97, n. 3, p. 454–464, 1 mar. 2022. Disponível em: https://www.mayoclinicproceedings.org/article/S0025-6196(21)00888-0/fulltext. Acesso em: 10 jan. 2026.
GOMES, S. M. R. et al. High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients. PLOS ONE, [S. l.], v. 18, n. 4, p. e0283983, 5 abr. 2023. Disponível em: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0283983. Acesso em: 10 jan. 2026.
GREENHALGH, T. et al. Long COVID: a clinical update. The Lancet, [S. l.], v. 404, n. 10453, p. 707–724, 17 ago. 2024. Disponível em: https://www.sciencedirect.com/science/article/pii/S014067362401136X. Acesso em: 8 nov. 2024.
GUARIENTI, F. A. et al. COVID-19: a multi-organ perspective. Frontiers in Cellular and Infection Microbiology, [S. l.], v. 14, 18 out. 2024. Disponível em: https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2024.1425547/full. Acesso em: 11 mar. 2025.
HAWLEY, H. B. Long COVID: Clinical Findings, Pathology, and Endothelial Molecular Mechanisms. The American Journal of Medicine, [S. l.], v. 138, n. 1, p. 91–97, 1 jan. 2025. Disponível em: https://www.sciencedirect.com/science/article/pii/S0002934323005399. Acesso em: 11 mar. 2025.
HURME, A. et al. Post-COVID-19 condition in prospective inpatient and outpatient cohorts. Scientific Reports, [S. l.], v. 15, p. 6925, 26 fev. 2025. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11865615/. Acesso em: 10 jan. 2026.
KENJI SUDO, F. et al. Cognitive, behavioral, neuroimaging and inflammatory biomarkers after hospitalization for COVID-19 in Brazil. Brain, Behavior, and Immunity, [S. l.], v. 115, p. 434–447, 1 jan. 2024. Disponível em: https://www.sciencedirect.com/science/article/pii/S0889159123003185. Acesso em: 10 jan. 2026.
LEMOS, F. F. B. et al. Prognostic significance of cytokine dysregulation in critically ill COVID-19 patients. Cytokine, [S. l.], v. 187, p. 156867, 1 mar. 2025. Disponível em: https://www.sciencedirect.com/science/article/pii/S1043466625000146. Acesso em: 27 fev. 2025.
LÓPEZ-SAMPALO, A.; BERNAL-LÓPEZ, M. R.; GÓMEZ-HUELGAS, R. Persistent COVID-19 syndrome. A narrative review. Revista Clínica Española (English Edition), [S. l.], v. 222, n. 4, p. 241–250, 1 abr. 2022. Disponível em: https://www.sciencedirect.com/science/article/pii/S225488742200008X. Acesso em: 11 mar. 2025.
LU, S. et al. Early biological markers of post-acute sequelae of SARS-CoV-2 infection. Nature Communications, [S. l.], v. 15, p. 7466, 29 ago. 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11358427/. Acesso em: 10 jan. 2026.
MAKI, F. M.; AL-THWANI, A. N.; JIAD, K. S. Study of some immunological signatures and their association with COVID-19 in a sample of recovered Iraqi patients. Immunobiology, [S. l.], v. 228, n. 2, p. 152348, 1 mar. 2023. Disponível em: https://www.sciencedirect.com/science/article/pii/S0171298523000165. Acesso em: 10 jan. 2026.
MCELVANEY, O. J. et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. American Journal of Respiratory and Critical Care Medicine, [S. l.], v. 202, n. 6, p. 812–821, 15 set. 2020.
MENEZES, D. C. de et al. Metabolic Profile of Patients with Long COVID: A Cross-Sectional Study. Nutrients, [S. l.], v. 15, n. 5, p. 1197, jan. 2023. Disponível em: https://www.mdpi.com/2072-6643/15/5/1197. Acesso em: 7 ago. 2024.
MENIAILO, M. E. et al. Interleukin-8 favors pro-inflammatory activity of human monocytes/macrophages. International Immunopharmacology, [S. l.], v. 56, p. 217–221, mar. 2018.
MROUEH, A. et al. COVID-19 promotes endothelial dysfunction and thrombogenicity: role of proinflammatory cytokines/SGLT2 prooxidant pathway. Journal of Thrombosis and Haemostasis, [S. l.], v. 22, n. 1, p. 286–299, 1 jan. 2024. Disponível em: https://www.jthjournal.org/article/S1538-7836(23)00724-9/fulltext. Acesso em: 10 jan. 2026.
MUELLER, M. R. et al. Long COVID: emerging pathophysiological mechanisms. Minerva medica, [S. l.], v. 116, n. 2, p. 156–165, 1 abr. 2025. Disponível em: https://doi.org/10.23736/S0026-4806.25.09539-4. Acesso em: 23 fev. 2026.
MÜLLER, L.; DI BENEDETTO, S. Immunosenescence and inflammaging: Mechanisms and modulation through diet and lifestyle. Frontiers in Immunology, [S. l.], v. 16, 4 dez. 2025. Disponível em: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1708280/full. Acesso em: 23 fev. 2026.
MUNN, Z. et al. Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews. JBI Evidence Synthesis, [S. l.], v. 21, n. 3, p. 467, mar. 2023. Disponível em: https://journals.lww.com/jbisrir/fulltext/2023/03000/assessing_the_risk_of_bias_of_quantitative.2.aspx. Acesso em: 20 mar. 2025.
NALBANDIAN, A. et al. Post-acute COVID-19 syndrome. Nature Medicine, [S. l.], v. 27, n. 4, p. 601–615, abr. 2021. Disponível em: https://www.nature.com/articles/s41591-021-01283-z. Acesso em: 23 fev. 2026.
NIKKHOO, B. et al. Elevated interleukin (IL)-6 as a predictor of disease severity among Covid-19 patients: a prospective cohort study. BMC infectious diseases, [S. l.], v. 23, n. 1, p. 311, 9 maio 2023.
OUZZANI, M. et al. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews, [S. l.], v. 5, n. 1, p. 210, 5 dez. 2016. Disponível em: https://doi.org/10.1186/s13643-016-0384-4. Acesso em: 20 jan. 2026.
PAGE, M. J. et al. [The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsDeclaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas]. Revista Panamericana De Salud Publica = Pan American Journal of Public Health, [S. l.], v. 46, p. e112, 2022.
PATTERSON, B. K. et al. Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning. Frontiers in Immunology, [S. l.], v. 12, 28 jun. 2021. Disponível em: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.700782/full. Acesso em: 10 jan. 2026.
PELUSO, M. J. et al. Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. Neurology Neuroimmunology & Neuroinflammation, [S. l.], v. 9, n. 5, p. e200003, set. 2022. Disponível em: https://www.neurology.org/doi/10.1212/NXI.0000000000200003. Acesso em: 10 jan. 2026.
PHETSOUPHANH, C. et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nature Immunology, [S. l.], v. 23, n. 2, p. 210–216, fev. 2022.
POPA, E. et al. The Molecular Mechanisms of Cognitive Dysfunction in Long COVID: A Narrative Review. International Journal of Molecular Sciences, [S. l.], v. 26, n. 11, p. 5102, 26 maio 2025.
PROAL, A. D.; VANELZAKKER, M. B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Frontiers in Microbiology, [S. l.], v. 12, p. 698169, 2021.
QIAN, G.; MAHDI, A. Sensitivity analysis methods in the biomedical sciences. Mathematical Biosciences, [S. l.], v. 323, p. 108306, maio 2020.
RODRIGUES, R. S. et al. Increased Lung Immune Metabolic Activity in COVID-19 Survivors. Clinical Nuclear Medicine, [S. l.], v. 47, n. 12, p. 1019, dez. 2022. Disponível em: https://journals.lww.com/nuclearmed/abstract/2022/12000/increased_lung_immune_metabolic_activity_in.2.aspx. Acesso em: 10 jan. 2026.
RODRIGUES, T. S. et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. The Journal of Experimental Medicine, [S. l.], v. 218, n. 3, p. e20201707, 1 mar. 2021.
SANTANA-DE ANDA, K. et al. Novel Clinical, Immunological, and Metabolic Features Associated with Persistent Post-Acute COVID-19 Syndrome. International Journal of Molecular Sciences, [S. l.], v. 25, n. 17, p. 9661, 6 set. 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11395921/. Acesso em: 10 jan. 2026.
SBIERSKI-KIND, J. et al. Persistent immune abnormalities discriminate post-COVID syndrome from convalescence. Infection, [S. l.], v. 52, n. 3, p. 1087–1097, 1 jun. 2024. Disponível em: https://doi.org/10.1007/s15010-023-02164-y. Acesso em: 10 jan. 2026.
SCHULTHEISS, C. et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Reports Medicine, [S. l.], v. 3, n. 6, p. 100663, 21 jun. 2022. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC9214726/. Acesso em: 10 jan. 2026.
SEKAR, P. et al. Post-COVID-19 Complications: A Study on Long COVID Symptoms and Their Pathophysiology. Journal of Pharmacy & Bioallied Sciences, [S. l.], v. 17, n. Suppl 3, p. S2557–S2559, set. 2025. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC12563606/. Acesso em: 10 jan. 2026.
SERAPIDE, F. et al. Lights and Shadows of Long COVID: Are Latent Infections the Real Hidden Enemy? Journal of Clinical Medicine, [S. l.], v. 13, n. 23, p. 7124, 25 nov. 2024.
SHEN, X.-L. et al. Clinical features and predictive nomogram for fatigue sequelae in non-severe patients infected with SARS-CoV-2 Omicron variant in Shanghai, China. Brain, Behavior, & Immunity - Health, [S. l.], v. 42, p. 100889, 18 out. 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11532739/. Acesso em: 10 jan. 2026.
SU, Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell, [S. l.], v. 185, n. 5, p. 881-895.e20, 3 mar. 2022.
TANG, N. et al. Blood Markers Show Neural Consequences of LongCOVID-19. Cells, [S. l.], v. 13, n. 6, p. 478, 8 mar. 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10969290/. Acesso em: 10 jan. 2026.
TEIXEIRA, E. P.; LYNN, F. A.; SOUZA, M. de L. de. GUIA PARA REVISÃO SISTEMATICA DE ESTUDOS OBSERVACIONAIS. Texto & Contexto - Enfermagem, [S. l.], v. 33, p. e20230221, 13 maio 2024. Disponível em: https://www.scielo.br/j/tce/a/876BLxXM3XxsXZTwGXSKCKM/?lang=pt&utm_source=chatgpt.com. Acesso em: 12 mar. 2025.
TORKI, E. et al. The demographic, laboratory and genetic factors associated with long Covid-19 syndrome: a case–control study. Clinical and Experimental Medicine, [S. l.], v. 24, n. 1, p. 1, 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10794331/. Acesso em: 10 jan. 2026.
VALENTE CORONEL, P. M. et al. Involvement of oxidative stress in post-acute sequelae of COVID-19: clinical implications. Redox Report: Communications in Free Radical Research, [S. l.], v. 30, n. 1, p. 2471738, dez. 2025.
WAN, X. et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC medical research methodology, [S. l.], v. 14, p. 135, 19 dez. 2014.
WANG, K. et al. Sequential multi-omics analysis identifies clinical phenotypes and predictive biomarkers for long COVID. Cell Reports Medicine, [S. l.], v. 4, n. 11, p. 101254, 21 nov. 2023. Disponível em: https://www.sciencedirect.com/science/article/pii/S2666379123004317. Acesso em: 10 jan. 2026.
YANG, S.-R. et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. American Journal of Physiology. Lung Cellular and Molecular Physiology, [S. l.], v. 291, n. 1, p. L46-57, jul. 2006.
YASEEN, M. M.; ABUHARFEIL, N. M.; DARMANI, H. The role of IL-1β during human immunodeficiency virus type 1 infection. Reviews in Medical Virology, [S. l.], v. 33, n. 1, p. e2400, 2023. Disponível em: https://onlinelibrary.wiley.com/doi/abs/10.1002/rmv.2400. Acesso em: 2 jun. 2025.
ZHANG, J. et al. In-depth analysis of the risk factors for persistent severe acute respiratory syndrome coronavirus 2 infection and construction of predictive models: an exploratory research study. BMC Infectious Diseases, [S. l.], v. 25, p. 699, 14 maio 2025. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC12080215/. Acesso em: 10 jan. 2026.
ZHANG, P. et al. Elevated interleukin-6 and adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates. Immunogenetics, [S. l.], v. 72, n. 8, p. 431–437, out. 2020.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2026 Amanda dos Santos de Amorim, Evailson Ferreira Porto, Caroline Tianeze de Castro, Fabrício Freire de Melo, Márcio Vasconcelos Oliveira
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
- Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista;
- Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista, desde que adpatado ao template do repositório em questão;
- Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado (Veja O Efeito do Acesso Livre).
- Os autores são responsáveis por inserir corretamente seus dados, incluindo nome, palavras-chave, resumos e demais informações, definindo assim a forma como desejam ser citados. Dessa forma, o corpo editorial da revista não se responsabiliza por eventuais erros ou inconsistências nesses registros.
POLÍTICA DE PRIVACIDADE
Os nomes e endereços informados nesta revista serão usados exclusivamente para os serviços prestados por esta publicação, não sendo disponibilizados para outras finalidades ou a terceiros.
Obs: todo o conteúdo do trabalho é de responsabilidade do autor e orientador.
